{"id":115776,"date":"2022-06-17T10:21:53","date_gmt":"2022-06-17T08:21:53","guid":{"rendered":"https:\/\/semmelweis.hu\/hirek\/?p=115776"},"modified":"2024-05-06T09:27:05","modified_gmt":"2024-05-06T07:27:05","slug":"tudomanyos-hirado-10","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/hirek\/2022\/06\/17\/tudomanyos-hirado-10\/","title":{"rendered":"Tudom\u00e1nyos h\u00edrad\u00f3 10."},"content":{"rendered":"
Tudom\u00e1nyos H\u00edrad\u00f3 c\u00edm\u0171 cikksorozatunkban az egyetemhez k\u00f6thet\u0151 D1 min\u0151s\u00edt\u00e9s\u0171 tudom\u00e1nyos k\u00f6zlem\u00e9nyekr\u0151l olvashat\u00f3 r\u00f6vid \u00f6sszefoglal\u00f3. A cikkeket az elm\u00falt id\u0151szak megjelen\u00e9sei alapj\u00e1n a K\u00f6zponti K\u00f6nyvt\u00e1r, illetve dr. Szigeti Gyula innov\u00e1ci\u00f3s igazgat\u00f3 v\u00e1logatta.<\/div>\n
Mesters\u00e9ges intelligenci\u00e1n alapul\u00f3 sz\u00f6veti mikroRNS-ek seg\u00edthetik a mell\u00e9kvese daganatainak diagn\u00f3zis\u00e1t<\/h5>\n
\"\"<\/a>A mell\u00e9kves\u00e9t \u00e9rint\u0151 daganatok gyakoriak, hiszen ak\u00e1r minden 20. embern\u00e9l el\u0151fordulnak a nagy felbont\u00e1s\u00fa k\u00e9palkot\u00f3 vizsg\u00e1latok tan\u00fas\u00e1gai alapj\u00e1n. E daganatok t\u00falnyom\u00f3 t\u00f6bbs\u00e9ge j\u00f3indulat\u00fa, azonban ritk\u00e1n rosszindulat\u00faak is el\u0151fordulnak, amelyek k\u00f3rj\u00f3slata rossz. A j\u00f3- \u00e9s rosszindulat\u00fa mell\u00e9kvese daganatok elk\u00fcl\u00f6n\u00edt\u00e9se id\u0151nk\u00e9nt igen nagy szakmai kih\u00edv\u00e1st jelent \u00e9s csapatmunk\u00e1t ig\u00e9nyel t\u00f6bbek k\u00f6z\u00f6tt endokrinol\u00f3gus, patol\u00f3gus \u00e9s radiol\u00f3gus orvosok bevon\u00e1s\u00e1val. A f\u0151 k\u00fcl\u00f6nbs\u00e9g, hogy a j\u00f3indulat\u00fa daganatok soha nem adnak \u00e1tt\u00e9tet. Tov\u00e1bb\u00e1, m\u00edg a rosszindulat\u00fa mell\u00e9kvese daganatokat \u00e1tt\u00e9tk\u00e9pz\u0151 hat\u00e1suk miatt mihamarabbi m\u0171t\u00e9ttel \u00e9s kemoter\u00e1pi\u00e1val kell kezelni, addig a j\u00f3indulat\u00fa daganatokat nem minden esetben sz\u00fcks\u00e9ges kezelni. Egym\u00e1st\u00f3l mer\u0151ben elt\u00e9r\u0151 lefoly\u00e1s\u00fa daganatokr\u00f3l van sz\u00f3, amelyek elk\u00fcl\u00f6n\u00edt\u00e9se meghat\u00e1roz\u00f3 a kimenetel szempontj\u00e1b\u00f3l. N\u00e9melykor azonban nagyon neh\u00e9z meghat\u00e1rozni a daganat viselked\u00e9s\u00e9t annak elt\u00e1vol\u00edt\u00e1sa n\u00e9lk\u00fcl.<\/div>\n
\u00a0<\/div>\n
Kutat\u00e1sunk sor\u00e1n a sejtjeink olyan molekul\u00e1it vizsg\u00e1ltuk, amelyek nem vesznek r\u00e9szt feh\u00e9rj\u00e9k k\u00f3dol\u00e1s\u00e1ban, az \u00fan. nem-k\u00f3dol\u00f3 RNS-eket. A nem-k\u00f3dol\u00f3 RNS-ek kifejez\u0151d\u00e9se a j\u00f3- \u00e9s rosszindulat\u00fa daganatok k\u00f6z\u00f6tt sokszor elt\u00e9r\u0151, \u00edgy alkalmasak lehetnek az elk\u00fcl\u00f6n\u00edt\u00e9s\u00fckre. Kiv\u00e1lasztva a szakirodalomban tal\u00e1lt nem-k\u00f3dol\u00f3 RNS-ek egy csoportj\u00e1t, az \u00fan. mikro RNS-eket, egy mesters\u00e9ges intelligenci\u00e1n alapul\u00f3, g\u00e9pi tanul\u00e1st alkalmaz\u00f3 m\u00f3dszerrel olyan mikro RNS kombin\u00e1ci\u00f3kat hoztunk l\u00e9tre, amelyek 90% f\u00f6l\u00f6tti \u00e9rz\u00e9kenys\u00e9ggel \u00e9s fajlagoss\u00e1ggal k\u00e9pesek elk\u00fcl\u00f6n\u00edteni egym\u00e1st\u00f3l a j\u00f3- \u00e9s rosszindulat\u00fa mell\u00e9kvesek\u00e9reg daganatokat. Kombin\u00e1ci\u00f3inkat beny\u00fajtottuk szabadalmi elb\u00edr\u00e1l\u00e1s al\u00e1 \u2013 foglalta \u00f6ssze dr. Turai P\u00e9ter Istv\u00e1n<\/div>\n
\u00a0<\/div>\n
Tissue miRNA Combinations for the Differential Diagnosis of Adrenocortical Carcinoma and Adenoma Established by Artificial Intelligence
\nP\u00e9ter Istv\u00e1n Turai (Department of Endocrinology, ENS@T Research Center of Excellence, Faculty of Medicine, Semmelweis University; Department of Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University; MTA-SE Molecular Medicine Research Group, E\u00f6tv\u00f6s Lor\u00e1nd Research Network), Zolt\u00e1n Herold (Division of Oncology, Department of Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University), G\u00e1bor Nyir\u0151 (Department of Endocrinology, ENS@T Research Center of Excellence, Faculty of Medicine, Semmelweis University; MTA-SE Molecular Medicine Research Group, E\u00f6tv\u00f6s Lor\u00e1nd Research Network; Department of Laboratory Medicine, Faculty of Medicine, Semmelweis University), Katalin Borka (2nd Department of Pathology, Semmelweis University), Tam\u00e1s Micsik (1st Department of Pathology and Experimental Cancer Research, Semmelweis University), Judit T\u0151ke (Department of Endocrinology, ENS@T Research Center of Excellence, Faculty of Medicine, Semmelweis University; Department of Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University), Nikolette Sz\u00fccs (Department of Endocrinology, ENS@T Research Center of Excellence, Faculty of Medicine, Semmelweis University; Department of Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University), Mikl\u00f3s T\u00f3th (Department of Endocrinology, ENS@T Research Center of Excellence, Faculty of Medicine, Semmelweis University; Department of Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University), Attila Pat\u00f3cs (Department of Laboratory Medicine, Faculty of Medicine, Semmelweis University; MTA-SE Hereditary Tumors Research Group, E\u00f6tv\u00f6s Lor\u00e1nd Research Network; Department of Molecular Genetics, National Institute of Oncology), Peter Igaz (Department of Endocrinology, ENS@T Research Center of Excellence, Faculty of Medicine, Semmelweis University; Department of Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University; MTA-SE Molecular Medicine Research Group, E\u00f6tv\u00f6s Lor\u00e1nd Research Network)
\nCancers,\u00a02022,\u00a014<\/em>(4), 895;\u00a0
\nhttps:\/\/doi.org\/10.3390\/cancers14040895<\/a><\/p>\n<\/div>\n
\u00a0<\/div>\n
R<\/strong>enin-Angiotenzin-Aldoszteron Rendszer G\u00e1tl\u00f3k \u00e9s az Immunellen\u00f6rz\u0151pont-G\u00e1tl\u00f3 Kezel\u00e9sben R\u00e9szes\u00fcl\u0151 Hipert\u00f3ni\u00e1s Daganatos Betegek T\u00fal\u00e9l\u00e9se<\/h5>\n

\"\"<\/a>Pre-klinikai vizsg\u00e1latok alapj\u00e1n felmer\u00fcl a renin-angiotenzin-aldoszteron rendszer g\u00e1tl\u00f3k (RAASi) j\u00f3t\u00e9kony hat\u00e1sa k\u00fcl\u00f6nb\u00f6z\u0151 t\u00edpus\u00fa daganatos betegek t\u00fal\u00e9l\u00e9s\u00e9ben. Kev\u00e9s adat \u00e1ll rendelkez\u00e9sre arra vonatkoz\u00f3an, hogy a RAASi-k haszn\u00e1lata milyen hat\u00e1ssal van a t\u00fal\u00e9l\u00e9sre azon daganatos betegekn\u00e9l, akik immunellen\u0151rz\u0151pont-g\u00e1tl\u00f3 (ICI) ter\u00e1pi\u00e1ban r\u00e9szes\u00fclnek. Jelen vizsg\u00e1latunk sor\u00e1n retrospekt\u00edv m\u00f3don elemezt\u00fck azon betegek adatait, akik ICI ter\u00e1pi\u00e1ban r\u00e9szes\u00fcltek a Massachusetts General K\u00f3rh\u00e1zban. \u00d6sszesen 10,903 betegb\u0151l 5,910 beteg szedett antihipertenz\u00edv gy\u00f3gyszert: 3,426 szedett RAASi-t, \u00e9s 2,484 egy\u00e9b t\u00edpus\u00fa antihipertenz\u00edv gy\u00f3gyszert. Vizsg\u00e1latunkban az els\u0151dleges v\u00e9gpont a teljes t\u00fal\u00e9l\u00e9s volt, valamint alcsoport anal\u00edzist is v\u00e9gezt\u00fcnk daganatt\u00edpusonk\u00e9nt.<\/p>\n

A leggyakoribb daganatt\u00edpusok a mellkasi daganatok (34%) \u00e9s a melanoma (16%) voltak. A RAASi-t szed\u0151 betegek id\u0151sebbek voltak, t\u00f6bb volt k\u00f6z\u00f6tt\u00fck a f\u00e9rfi, \u00e9s t\u00f6bb kardiovaszkul\u00e1ris rizik\u00f3faktorral rendelkeztek. Cox-f\u00e9le ar\u00e1nyos haz\u00e1rd modellben, a RAASi egyidej\u0171 haszn\u00e1lata ICI ter\u00e1pia sor\u00e1n szignifik\u00e1nsan jobb teljes t\u00fal\u00e9l\u00e9ssel t\u00e1rsult (relat\u00edv kock\u00e1zat (HR):0,92, [95% konfidencia intervallum (CI):0,85-0,99], P<\/em>=0,032). Alcsoport anal\u00edzis sor\u00e1n, a gasztrointesztin\u00e1lis (HR:0,82, [95% CI:0,67-1,01], P<\/em>=0,057) \u00e9s a genitourin\u00e1ris (HR:0,81, [95% CI:0,64-1,01], P<\/em>=0,067) daganattal rendelkez\u0151 betegek eset\u00e9ben tal\u00e1ltuk a legnagyobb hozad\u00e9k\u00e1t a RAASi ter\u00e1pi\u00e1nak. Nagysz\u00e1m\u00fa hipert\u00f3ni\u00e1s \u00e9s daganatos beteg retrospekt\u00edv elemz\u00e9se sor\u00e1n, azon betegek eset\u00e9ben, akik az ICI ter\u00e1pia kezdetekor RAASi-t is szedtek, hosszabb teljes t\u00fal\u00e9l\u00e9st tal\u00e1ltunk. A RAASi-hoz t\u00e1rsul\u00f3 hosszabb teljes t\u00fal\u00e9l\u00e9s a gasztrointesztin\u00e1lis \u00e9s genitourin\u00e1ris daganattal rendelkez\u0151 betegek eset\u00e9ben volt a legjelent\u0151sebb. Eredm\u00e9nyeink alapj\u00e1n prospekt\u00edv randomiz\u00e1lt vizsg\u00e1latok elv\u00e9gz\u00e9se sz\u00fcks\u00e9ges azon daganatos betegek azonos\u00edt\u00e1s\u00e1ra, akikn\u00e9l hozad\u00e9ka lehet a RAASi megkezd\u00e9s\u00e9nek ICI ter\u00e1pia sor\u00e1n – \u00edrta \u00f6sszefoglal\u00f3j\u00e1ban dr. Drobni Zs\u00f3fia D\u00f3ra.<\/p>\n

\n

Renin\u2013angiotensin\u2013aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors
\nZsofia D. Drobni (Heart and Vascular Center, Semmelweis University; Cardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School), Olivier Michielin (Oncology Department, Precision Oncology Center; Oncology Department, Lausanne University Hospital), Thiago Quinaglia (Cardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School), Daniel A. Zlotoff (Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School), Leyre Zubiri (Division of Oncology and Hematology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School), Hannah K. Gilman (Cardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School), Sama Supraja (Cardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School), Bela Merkely (Heart and Vascular Center, Semmelweis University), Veronika Muller (Department of Pulmonology, Semmelweis University), Ryan J. Sullivan (Division of Oncology and Hematology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School), Kerry L. Reynolds (Division of Oncology and Hematology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School), Michael J. Pittet (Department of Pathology and Immunology, University of Geneva), Rakesh K. Jain (Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School), Tomas G. Neilan (Cardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School; Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School)
\nEuropean Journal of Cancer,, Volume 163, 2022, Pages 108-118,
\nhttps:\/\/doi.org\/10.1016\/j.ejca.2021.12.024.<\/a><\/p>\n<\/div>\n

\n
Testi sz\u00e9gyen \u00e9s b\u0171ntudat ev\u00e9szavarokban: A maladapt\u00edv ev\u00e9si magatart\u00e1s emocion\u00e1lis h\u00e1tter\u00e9nek vizsg\u00e1lata magyar \u00e9s norv\u00e9g egyetemist\u00e1k k\u00f6r\u00e9ben.<\/span><\/h5>\n<\/div>\n

\"\"<\/a>Az ev\u00e9szavarok nem csak lelki, hanem testi k\u00f6vetkezm\u00e9nyekkel, s\u00falyos t\u00fcnetek eset\u00e9n jelent\u0151s mortalit\u00e1si kock\u00e1zattal j\u00e1rnak. Az egyetemista koroszt\u00e1ly az ev\u00e9szavar t\u00fcnetek kialakul\u00e1sa tekintet\u00e9ben vesz\u00e9lyeztetettnek tekinthet\u0151. Az ev\u00e9szavarok pszichol\u00f3giai h\u00e1tter\u00e9nek felt\u00e1r\u00e1sa a korai diagnosztika \u00e9s az adekv\u00e1t ter\u00e1pi\u00e1s ell\u00e1t\u00e1s tervez\u00e9se szempontj\u00e1b\u00f3l alapvet\u0151 jelent\u0151s\u00e9g\u0171.<\/p>\n

Kutat\u00e1sunkban egy Conradt \u00e9s munkat\u00e1rsai (2007) \u00e1ltal n\u00e9met nyelvter\u00fcleten kifejlesztett r\u00f6vid, 12 t\u00e9teles, a tests\u00falyhoz \u00e9s testhez kapcsol\u00f3d\u00f3 sz\u00e9gyen \u00e9s b\u0171ntudat felm\u00e9r\u00e9s\u00e9re alkalmas \u00f6nkit\u00f6lt\u0151 k\u00e9rd\u0151\u00edv (Weight- and Body-related Shame and Guilt Scale, WEB-SG) magyar nyelv\u0171 adapt\u00e1l\u00e1s\u00e1t v\u00e9gezt\u00fck el. Ezen k\u00edv\u00fcl magyar \u00e9s norv\u00e9g egyetemista mint\u00e1n vizsg\u00e1ltuk meg a testi sz\u00e9gyen \u00e9s b\u0171ntudat kapcsolat\u00e1t az ev\u00e9szavarok t\u00fcneteivel, a t\u00fals\u00fallyal \u00e9s a kr\u00f3nikus sz\u00e9gyennel. F\u0151bb eredm\u00e9nyeink szerint a testi b\u0171ntudat az anorexia-specifikus korl\u00e1toz\u00f3 ev\u00e9si attit\u0171d\u00f6kkel \u00e1ll kapcsolatban, m\u00edg a magasabb testi sz\u00e9gyen magasabb tests\u00fallyal j\u00e1r egy\u00fctt, k\u00fcl\u00f6n\u00f6sen magyar mint\u00e1n. Eredm\u00e9nyeink felh\u00edvj\u00e1k a figyelmet arra, hogy a testtel kapcsolatos b\u0171ntudat \u00e9s sz\u00e9gyen kritikus t\u00e9nyez\u0151k az ev\u00e9szavarok felm\u00e9r\u00e9se \u00e9s kezel\u00e9se tekintet\u00e9ben – foglalta \u00f6ssze dr. Vizin Gabriella<\/p>\n

\n

Body-related shame or guilt? Dominant factors in maladaptive eating behaviors among Hungarian and Norwegian university students
\nGabriella Vizin (E\u00f6tv\u00f6s Lor\u00e1nd University, Institute of Psychology; Semmelweis University, Faculty of General Medicine, Department of Clinical Psychology), Zsolt Horv\u00e1th (E\u00f6tv\u00f6s Lor\u00e1nd University, Institute of Psychology; E\u00f6tv\u00f6s Lor\u00e1nd University, Doctoral School of Psychology), T\u00fcnde Vank\u00f3 (Mayfairtherapy Practice, 53 Davies Str, London), R\u00f3bert Urb\u00e1n (E\u00f6tv\u00f6s Lor\u00e1nd University, Institute of Psychology)
\nHeliyon, 2022 February, Volume 8, Issue 2, e08817
\nhttps:\/\/doi.org\/10.1016\/j.heliyon.2022.e08817<\/a><\/p>\n<\/div>\n

\n
A harmadik COVID-19 pand\u00e9mi\u00e1s hull\u00e1m jellemz\u0151i Magyarorsz\u00e1gon, k\u00fcl\u00f6n\u00f6s tekintettel a morbidit\u00e1s, mortalit\u00e1s, \u00e9s a COVID-19 elleni \u00e1toltotts\u00e1g t\u00e1rsadalmi-gazdas\u00e1gi helyzet szerinti egyenl\u0151tlens\u00e9geire<\/h5>\n<\/div>\n

\"\"<\/a>A J Pers Med-ben publik\u00e1lt k\u00f6zlem\u00e9ny a COVID-19 pand\u00e9mia 3. magyarorsz\u00e1gi hull\u00e1m\u00e1t vizsg\u00e1lja, amely a COVID-19-cel \u00f6sszef\u00fcgg\u0151 mortalit\u00e1st tekintve az eddigi legs\u00falyosabb volt. Az eg\u00e9szs\u00e9g\u00fcgyi, gazdas\u00e1gi, t\u00e1rsadalmi terheket jelent\u0151sen n\u00f6velte az 50-64 \u00e9ves koroszt\u00e1ly kiugr\u00f3an magas t\u00f6bblethal\u00e1loz\u00e1sa, mely a harmadik hull\u00e1mban 40%-kal haladta meg a 2014-19 azonos id\u0151szak \u00e1tlagos heti hal\u00e1loz\u00e1s\u00e1t. A publik\u00e1ci\u00f3 bemutatja a COVID-19 morbidit\u00e1s \u00e9s mortalit\u00e1s egyenl\u0151tlens\u00e9geit Magyarorsz\u00e1gon a harmadik hull\u00e1mban. A kedvez\u0151tlenebb t\u00e1rsadalmi-gazdas\u00e1gi helyzet\u0171 telep\u00fcl\u00e9seken \u00e9l\u0151k k\u00f6r\u00e9ben az orsz\u00e1gos \u00e1tlagt\u00f3l alacsonyabb volt a regisztr\u00e1lt COVID-19 esetek, de magasabb volt a hal\u00e1loz\u00e1s gyakoris\u00e1ga, amely a megbeteged\u00e9sek jelent\u0151s aluldetekt\u00e1lts\u00e1g\u00e1t val\u00f3sz\u00edn\u0171s\u00edti ezeken a telep\u00fcl\u00e9seken.<\/p>\n

A COVID-19 elleni v\u00e9d\u0151olt\u00e1si program m\u00e1r a m\u00e1sodik hull\u00e1m v\u00e9g\u00e9n megkezd\u0151d\u00f6tt, azonban az egyenl\u0151tlens\u00e9gek id\u0151vel az \u00e1toltotts\u00e1gban is megmutatkoztak. A harmadik j\u00e1rv\u00e1nyhull\u00e1m v\u00e9g\u00e9n a legkedvez\u0151tlenebb t\u00e1rsadalmi gazdas\u00e1gi helyzet\u0171 telep\u00fcl\u00e9si kvintilis lakoss\u00e1g\u00e1nak az \u00e1toltotts\u00e1ga 38%-kal volt alacsonyabb az orsz\u00e1gos \u00e1tlagn\u00e1l, azaz \u00e9pp azokon a ter\u00fcleteken detekt\u00e1ltak a szerz\u0151k szignifik\u00e1nsan alacsonyabb \u00e1toltotts\u00e1got, ahol a kedvez\u0151tlen t\u00e1rsadalmi-gazdas\u00e1gi helyzet\u0171 telep\u00fcl\u00e9sek magas mortalit\u00e1si kock\u00e1zat\u00fa lakoss\u00e1ga \u00e9l. A megbeteged\u00e9si \u00e9s hal\u00e1loz\u00e1si tendenci\u00e1k t\u00e1rsadalmi-gazdas\u00e1gi kateg\u00f3ri\u00e1kkal val\u00f3 ellent\u00e9tes kapcsolata aggodalomra ad okot, \u00e9s r\u00e1mutat esetlegesen elmaradt prevenci\u00f3s int\u00e9zked\u00e9sekre, valamint adekv\u00e1t v\u00e1laszl\u00e9p\u00e9sek sz\u00fcks\u00e9gess\u00e9g\u00e9re – fogalmazott \u00f6sszefoglal\u00f3j\u00e1ban dr. Oroszi Beatrix.<\/p>\n

\n

Characteristics of the Third COVID-19 Pandemic Wave with Special Focus on Socioeconomic Inequalities in Morbidity, Mortality and the Uptake of COVID-19 Vaccination in Hungary
\nBeatrix Oroszi (Epidemiology and Surveillance Centre, Semmelweis University), Attila Juh\u00e1sz (Department of Public Health, Government Office of Capital City Budapest), Csilla Nagy (Department of Public Health, Government Office of Capital City Budapest), Judit Krisztina Horv\u00e1th (Epidemiology and Surveillance Centre, Semmelweis University), Krisztina Eszter Koml\u00f3s (Epidemiology and Surveillance Centre, Semmelweis University), Gerg\u0151 T\u00fari (Epidemiology and Surveillance Centre, Semmelweis University), Martin McKee (Epidemiology and Surveillance Centre, Semmelweis University), R\u00f3za \u00c1d\u00e1ny (MTA-DE-Public Health Research Group, Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen; Department of Public Health, Faculty of Medicine, Semmelweis University)
\nJ. Pers. Med.,\u00a02022,\u00a012(3), 388
\nhttps:\/\/doi.org\/10.3390\/jpm12030388<\/a><\/p>\n<\/div>\n

A COVID-19 j\u00e1rv\u00e1ny hat\u00e1sa az autoimmun vizsg\u00e1latokra Eur\u00f3p\u00e1ban. Tanuls\u00e1gok egy nemzetk\u00f6zi felm\u00e9r\u00e9s kapcs\u00e1n<\/h5>\n

\"\"<\/a>A COVID-19 vil\u00e1gj\u00e1rv\u00e1ny els\u0151 hull\u00e1ma \u00faj kih\u00edv\u00e1sok el\u00e9 \u00e1ll\u00edtotta az eg\u00e9szs\u00e9g\u00fcgyi ell\u00e1t\u00e1st az eg\u00e9sz vil\u00e1gon. Munk\u00e1nk c\u00e9lja az autoantitest vizsg\u00e1latok alakul\u00e1s\u00e1nak felm\u00e9r\u00e9se a COVID-19 j\u00e1rv\u00e1ny ideje alatt az eur\u00f3pai orsz\u00e1gokban, melyet a European Autoimmunity Standardisation Initiative (EASI) kezdem\u00e9nyez\u00e9s\u00e9re v\u00e9gezt\u00fck.<\/p>\n

10 autoantitestre vonatkoz\u00f3an gy\u0171jt\u00f6tt\u00fck be a vizsg\u00e1latok sz\u00e1m\u00e1ra \u00e9s a pozit\u00edv eredm\u00e9nyek sz\u00e1m\u00e1ra vonatkoz\u00f3 adatokat a j\u00e1rv\u00e1nyt megel\u0151z\u0151 2019-es, valamint a j\u00e1rv\u00e1ny 2020-as \u00e9v\u00e9re vonatkoz\u00f3an 15 eur\u00f3pai orsz\u00e1g 97 klinikai laborat\u00f3rium\u00e1b\u00f3l. Az autoantitest vizsg\u00e1latok sz\u00e1m\u00e1nak 13%-os cs\u00f6kken\u00e9s\u00e9t tapasztaltuk 2020-ban 2019-hez k\u00e9pest. A cs\u00f6kken\u00e9s a j\u00e1rv\u00e1ny els\u0151 hull\u00e1ma alatt volt a legmagasabb (45,2%).\u00a0 B\u00e1r a m\u00e1sodik hull\u00e1mban a cs\u00f6kken\u00e9s m\u00e9rs\u00e9kl\u0151d\u00f6tt (6,8%), m\u00edg n\u00e9h\u00e1ny orsz\u00e1gban a vizsg\u00e1latok sz\u00e1ma alig v\u00e1ltozott, bizonyos orsz\u00e1gokban \u00fajabb jelent\u0151s cs\u00f6kken\u00e9s volt tapasztalhat\u00f3. N\u00e9melyik autoantitest eset\u00e9n a pozit\u00edv eredm\u00e9nyek ar\u00e1ny\u00e1ban is voltak kisebb k\u00fcl\u00f6nbs\u00e9gek, de \u00f6sszess\u00e9g\u00e9ben a pozit\u00edv eredm\u00e9nyek ar\u00e1nya a k\u00e9t \u00e9vben hasonl\u00f3 volt. Eredm\u00e9nyeink az autoimmun vizsg\u00e1latok \u00f6sszehangol\u00e1s\u00e1ra ir\u00e1nyul\u00f3 hat\u00e9kony strat\u00e9gia fontoss\u00e1g\u00e1ra h\u00edvj\u00e1k fel a figyelmet hasonl\u00f3 kritikus helyzetekben – foglalta \u00f6ssze dr. Nagy Eszter.<\/p>\n

\n

The impact of the COVID-19 pandemic on autoimmune diagnostics in Europe: A lesson to be learned
\nEszter Nagy (National Institute of Locomotor diseases and Disabilities; Department of Laboratory Medicine, Semmelweis University), Maria Infantino (Immunologia Allergologia, Dipartimento di Medicina di Laboratorio, Ospedale San Giovanni di Dio Azienda, Usl Toscana Centro), Nicola Bizzaro (Laboratorio di Patologia Clinica, Ospedale San Antonio (Tolmezzo), Azienda Sanitaria Universitaria Integrata), Hristina Andreeva (Division of Immunology and Transfusion Medicine, Department of Laboratory Medicine,<\/strong> University Hospital of North Norway), Hetty J. Bontkes (Department of Clinical Chemistry, Medical Immunology Laboratory, Amsterdam Infection & Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam), Xavier Bossuyt (Department of Microbiology, Immunology and Transplantation, KU Leuven and Laboratory Medicine, University Hospital Leuven), Nicole Fabien (Department of Immunology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon), Katarzyna Fischer (Individual Laboratory for Rheumatologic Diagnostics, Pomeranian Medical University in Szczecin), Ingmar A.F.M.<\/span>\u00a0Heijnen (Medical Immunology, Laboratory Medicine, University Hospital Basel), Manfred Herold (Medical University of Innsbruck, Department of Internal Medicine II, Rheumatology Laboratory), Ana<\/span>\u00a0Kozmar (Department of Laboratory Diagnostics, University Hospital Centre Zagreb), Liisa<\/span>\u00a0Kuhi (Central Laboratory, East Tallinn Central Hospital), Marcos<\/span>\u00a0L\u00f3pez-Hoyos (Servicio de Inmunolog\u00eda, Hospital Universitario Marqu\u00e9s de Valdecilla-IDIVAL, Universidad Cantabria), Rille<\/span>\u00a0Pullerits (The Sahlgrenska Academy at University of Gothenburg, Institution of Medicine, Department of Rheumatology and Inflammation Research; Sahlgrenska University Hospital, Department of Clinical Immunology and Transfusion Medicine), Maria Jos\u00e9 Rego<\/span>\u00a0Sousa (Centro de Medicina Laboratorial Germano de Sousa), Alexandra<\/span>\u00a0Tsirogianni (Immunology-Histocompatibility Department, „Evangelismos” General Hospital of Athens), Jan<\/span>\u00a0Damoiseaux (Central Diagnostic Laboratory, Maastricht University Medical Center), on behalf of the European Autoimmunity Standardisation Initiative
\nAutoimmunity Reviews,\u00a0<\/span>December 2021, <\/span>Volume 20, Issue 12, , 102985
\nhttps:\/\/doi.org\/10.1016\/j.autrev.2021.102985<\/a>
\n<\/span><\/p>\n<\/div>\n

PlatypOUs\u2014mobilis robot platform \u00e9s m\u00e9rn\u00f6kk\u00e9pz\u00e9sben alkalmazhat\u00f3 demonstr\u00e1ci\u00f3s eszk\u00f6z<\/h5>\n

\"\"<\/a>A PlatypOUs oktat\u00e1si c\u00e9lokat szolg\u00e1l\u00f3 mobilis robot platform a Semmelweis Egyetem \u00e9s az \u00d3budai Egyetem hallgat\u00f3inak k\u00f6z\u00f6s munk\u00e1ja, amely elektrofiziol\u00f3giai jeleket alkalmaz vez\u00e9rl\u0151 utas\u00edt\u00e1sokk\u00e9nt. A PlatypOUs hardveregys\u00e9ge Intel minisz\u00e1m\u00edt\u00f3g\u00e9pen alapul, differenci\u00e1lis hajt\u00e1st alkalmaz, tov\u00e1bb\u00e1 LIDAR-ral, m\u00e9lys\u00e9gi kamer\u00e1val \u00e9s inerci\u00e1lis m\u00e9r\u0151egys\u00e9ggel (gyorsul\u00e1sm\u00e9r\u0151 \u00e9s giroszk\u00f3p) felszerelt. Jelr\u00f6gz\u00edt\u0151 berendez\u00e9sk\u00e9nt egy, a magyar MindRove \u00e1ltal gy\u00e1rtott hordozhat\u00f3 elektroenkefalogr\u00e1fi\u00e1s eszk\u00f6zt alkalmaztunk. A robot h\u00e1romf\u00e9le utas\u00edt\u00e1st k\u00f6vet, ezek: 90\u00b0-os jobbra fordul\u00e1s, el\u0151re halad\u00e1s, illetve meg\u00e1ll\u00e1s. Egy, a platformhoz fejlesztett grafikus felhaszn\u00e1l\u00f3i fel\u00fclet az egyes utas\u00edt\u00e1soknak megfelel\u0151 elektrofiziol\u00f3giai mint\u00e1kat k\u00e9r a felhaszn\u00e1l\u00f3t\u00f3l, majd ezekre tart\u00f3vektor-g\u00e9p alap\u00fa oszt\u00e1lyoz\u00f3t illeszt.<\/p>\n

M\u00e9r\u00e9seink alapj\u00e1n az oszt\u00e1lyoz\u00f3 a bemenet\u00e9n kapott mint\u00e1k 86,67%-\u00e1b\u00f3l k\u00e9pes helyes vez\u00e9rl\u0151jelet el\u0151\u00e1ll\u00edtani; mintak\u00f6vet\u00e9ses tesztek sor\u00e1n 12,39%-os \u00e1tlagos hib\u00e1val kellett sz\u00e1molnunk. Mindezek alapj\u00e1n a PlatypOUs a gyakorlatban haszn\u00e1lhat\u00f3 eszk\u00f6znek bizonyult, de a rendszer tov\u00e1bbi valid\u00e1ci\u00f3j\u00e1ra sz\u00fcks\u00e9g lesz a k\u00f6zelj\u00f6v\u0151ben – foglalta \u00f6ssze R\u00e1cz Melinda.<\/p>\n

\n

PlatypOUs\u2014A Mobile Robot Platform and Demonstration Tool Supporting STEM Education
\nMelinda R\u00e1cz (Research Centre for Natural Sciences, E\u00f6tv\u00f6s Lor\u00e1nd Research Network; J\u00e1nos Szent\u00e1gothai Doctoral School of Neurosciences, Semmelweis University; Selye J\u00e1nos Doctoral College for Advanced Studies, Semmelweis University), Erick Noboa (Antal Bejczy Center for Intelligent Robotics, Robotics Special College, University Research and Innovation Center, \u00d3buda University), Borsa D\u00e9t\u00e1r (Antal Bejczy Center for Intelligent Robotics, Robotics Special College, University Research and Innovation Center, \u00d3buda University), \u00c1d\u00e1m Nemes (Antal Bejczy Center for Intelligent Robotics, Robotics Special College, University Research and Innovation Center, \u00d3buda University), P\u00e9ter Galambos (Antal Bejczy Center for Intelligent Robotics, Robotics Special College, University Research and Innovation Center, \u00d3buda University; Biomatics and Applied Artificial Intelligence Institution, John von Neumann Faculty of Informatics, \u00d3buda University), L\u00e1szl\u00f3 Sz\u0171cs (Antal Bejczy Center for Intelligent Robotics, Robotics Special College, University Research and Innovation Center), Gergely M\u00e1rton (Research Centre for Natural Sciences, E\u00f6tv\u00f6s Lor\u00e1nd Research Network; MindRove Kft; Faculty of Information Technology and Bionics, P\u00e1zm\u00e1ny P\u00e9ter Catholic University), Gy\u00f6rgy Eigner (Antal Bejczy Center for Intelligent Robotics, Robotics Special College, University Research and Innovation Center, \u00d3buda University; Biomatics and Applied Artificial Intelligence Institution, John von Neumann Faculty of Informatics, \u00d3buda University; Physiological Controls Research Center, University Research and Innovation Center, \u00d3buda University), Tam\u00e1s Haidegger (Antal Bejczy Center for Intelligent Robotics, Robotics Special College, University Research and Innovation Center, \u00d3buda University; Biomatics and Applied Artificial Intelligence Institution, John von Neumann Faculty of Informatics, \u00d3buda University)
\nSensors\u00a02022,\u00a022(6), 2284;
\nhttps:\/\/doi.org\/10.3390\/s22062284<\/a><\/p>\n<\/div>\n

A r\u00f6vid \u00f6sszefoglal\u00f3kat a tudom\u00e1nyos publik\u00e1ci\u00f3k szerz\u0151i k\u00e9sz\u00edtett\u00e9k.
\nSzerkesztette: Szab\u00f3 \u00c1d\u00e1m
\nFot\u00f3: a publik\u00e1ci\u00f3kb\u00f3l sz\u00e1rmaz\u00f3 k\u00e9pek<\/p>\n","protected":false},"excerpt":{"rendered":"

Cikksorozatunkban az egyetemhez k\u00f6thet\u0151 D1 min\u0151s\u00edt\u00e9s\u0171 tudom\u00e1nyos k\u00f6zlem\u00e9nyekr\u0151l olvashat\u00f3 r\u00f6vid \u00f6sszefoglal\u00f3.<\/p>\n","protected":false},"author":101751,"featured_media":102156,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[161,168],"tags":[4179,2408,4276],"class_list":["post-115776","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tudomany","category-kiemelt","tag-alhonlapokra","tag-mki-alairas","tag-tudomanyos-hirado"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/posts\/115776","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/users\/101751"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/comments?post=115776"}],"version-history":[{"count":6,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/posts\/115776\/revisions"}],"predecessor-version":[{"id":139658,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/posts\/115776\/revisions\/139658"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/media\/102156"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/media?parent=115776"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/categories?post=115776"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/tags?post=115776"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}